Since EGFR and HER2 are predominantly expressed in the basal and luminal subtypes of bladder cancer, respectively, combining both targets provide a unique and highly selective way of targeting bladder cancers that have moderate expression of both [44]. Here, ERBB2 is linked to urinary bladder carcinoma.